Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  G1 Therapeutics, Inc.    GTHX

G1 THERAPEUTICS, INC.

(GTHX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2021 01/15/2021 01/19/2021 01/20/2021 01/21/2021 Date
20.67(c) 20.83(c) 21.69(c) 20.99(c) 20.93 Last
1 214 629 837 138 1 407 346 840 399 390 320 Volume
+5.89% +0.77% +4.13% -3.23% -0.29% Change
More quotes
Financials (USD)
Sales 2020 32,8 M - -
Net income 2020 -108 M - -
Net Debt 2020 - - -
P/E ratio 2020 -7,43x
Yield 2020 -
Sales 2021 15,3 M - -
Net income 2021 -164 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,37x
Yield 2021 -
Capitalization 799 M 799 M -
Capi. / Sales 2020 24,3x
Capi. / Sales 2021 52,2x
Nbr of Employees 104
Free-Float 88,8%
More Financials
Company
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It... 
More about the company
Notations Surperformance© of G1 Therapeutics, Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about G1 THERAPEUTICS, INC.
01/20Simcere Pharma Wins Regulatory Nod to Start Clinical Trial of Myelosuppressio..
MT
01/13G1 THERAPEUTICS : J.P. Morgan Healthcare Conference Presentation
PU
01/11G1 THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulatio..
AQ
01/05G1 THERAPEUTICS : Announces Appointment of William C. Roberts as Vice President,..
AQ
01/05G1 THERAPEUTICS : to Present at the 39th Annual J.P. Morgan Healthcare Conferenc..
AQ
01/04G1 THERAPEUTICS : Announces Appointment of William C. Roberts as Vice President,..
AQ
2020INSIDER TRENDS : Insider Sale at G1 Therapeutics Slowing 90-Days of Buying
MT
2020INSIDER TRENDS : G1 Therapeutics Sees 90 Days of Insider Buying Trend Reducing w..
MT
2020G1 Therapeutics Says Trilaciclib Study Showed Significant Improvement in Over..
MT
2020G1 THERAPEUTICS : Presents Final Phase 2 Clinical Data on Trilaciclib in Combina..
AQ
2020G1 THERAPEUTICS : Corporate Overview – December 2020
PU
2020G1 THERAPEUTICS : to Participate in the Evercore ISI 3rd Annual HealthCONx Confe..
AQ
2020G1 Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conf..
GL
2020G1 THERAPEUTICS : to Participate in the Evercore ISI 3rd Annual HealthCONx Confe..
AQ
2020INSIDER TRENDS : Insider Buying Continued with Purchase of G1 Therapeutics Stock
MT
More news
News in other languages on G1 THERAPEUTICS, INC.

- No features available -

More news
Chart G1 THERAPEUTICS, INC.
Duration : Period :
G1 Therapeutics, Inc. Technical Analysis Chart | GTHX | US3621LQ1099 | MarketScreener
Technical analysis trends G1 THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 50,00 $
Last Close Price 20,99 $
Spread / Highest target 291%
Spread / Average Target 138%
Spread / Lowest Target 0,05%
EPS Revisions
Managers and Directors
NameTitle
Jack Bailey President & Chief Executive Officer
Garry Allen Nicholson Chairman
Terry L. Murdock Chief Operating Officer
Jennifer K. Moses Chief Financial Officer
Jay C. Strum Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
G1 THERAPEUTICS, INC.16.68%799
GILEAD SCIENCES, INC.16.70%85 227
VERTEX PHARMACEUTICALS0.15%61 551
WUXI APPTEC CO., LTD.18.76%58 153
REGENERON PHARMACEUTICALS12.25%57 234
BEIGENE, LTD.40.41%33 081